West H - Search Results

1

Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block.

Liu J, Amini A, Govindarajan A, Abuali T, Mambetsariev I, Massarelli E, Villaflor V, Villalona-Calero M, West H, Williams T, Salgia R. Liu J, et al. Among authors: west h. JCO Precis Oncol. 2023 Sep;7:e2200445. doi: 10.1200/PO.22.00445. JCO Precis Oncol. 2023. PMID: 37656950 Review.

2

Jarring Discordance Between Idealized and Real-World Management in Stage III Non-Small-Cell Lung Cancer.

West HJ. West HJ. JCO Oncol Pract. 2020 Oct;16(10):628-630. doi: 10.1200/OP.20.00428. Epub 2020 Jun 23. JCO Oncol Pract. 2020. PMID: 32574126 No abstract available.

3

Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC).

Liu J, Bratton E, Yu X, Ladbury C, Wagner J, West H, Massarelli E, Salgia R, Pathak R, Villaflor V, Villalona-Calero M, Amini A. Liu J, et al. Among authors: west h. Am J Clin Oncol. 2022 Feb 1;45(2):49-54. doi: 10.1097/COC.0000000000000886. Am J Clin Oncol. 2022. PMID: 34991107

4

Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients.

Liu J, Ladbury C, Kim J, Raz D, Erhunmwunsee L, West HJ, Williams T, Salgia R, Massarelli E, Amini A. Liu J, et al. J Thorac Oncol. 2022 Feb;17(2):194-196. doi: 10.1016/j.jtho.2021.08.006. J Thorac Oncol. 2022. PMID: 35074226 Free article. No abstract available.

5

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC.

Novak J, Salgia R, West H, Villalona-Calero MA, Sampath S, Williams T, Villaflor V, Massarelli E, Pathak R, Koczywas M, Chau B, Amini A. Novak J, et al. Among authors: west h. Cancers (Basel). 2022 Aug 18;14(16):3983. doi: 10.3390/cancers14163983. Cancers (Basel). 2022. PMID: 36010982 Free PMC article. Review.

6

Perioperative Immune Checkpoint Inhibition in Early-Stage Non-Small Cell Lung Cancer: A Review.

Desai AP, Adashek JJ, Reuss JE, West HJ, Mansfield AS. Desai AP, et al. JAMA Oncol. 2023 Jan 1;9(1):135-142. doi: 10.1001/jamaoncol.2022.5389. JAMA Oncol. 2023. PMID: 36394834 Review.

7

Molecular Marker Testing in Curable Non-Small Cell Lung Cancer-Practice Necessarily Precedes Data.

Aggarwal C, West HJ. Aggarwal C, et al. JAMA Oncol. 2023 Jun 1;9(6):758-760. doi: 10.1001/jamaoncol.2023.0251. JAMA Oncol. 2023. PMID: 37052928

8

The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer.

Tam A, Eustace N, Kassardjian A, West H, Williams TM, Amini A. Tam A, et al. Among authors: west h. Surg Oncol Clin N Am. 2023 Jul;32(3):497-514. doi: 10.1016/j.soc.2023.02.004. Epub 2023 Apr 4. Surg Oncol Clin N Am. 2023. PMID: 37182989 Review.

9

Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.

West HJ, Kim JY. West HJ, et al. JAMA Oncol. 2024 Feb 1;10(2):249-255. doi: 10.1001/jamaoncol.2023.5276. JAMA Oncol. 2024. PMID: 38153722 Review.

10

Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting.

Gadgeel SM, Rai P, Annavarapu S, Alam S, Goldschmidt JH, West HJ, Santorelli M, Martins RE. Gadgeel SM, et al. Among authors: west hj. Front Oncol. 2024 Mar 8;14:1298603. doi: 10.3389/fonc.2024.1298603. eCollection 2024. Front Oncol. 2024. PMID: 38525422 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

553 results

Search Page

Filters